Search

Your search keyword '"Grosso F."' showing total 649 results
Start Over Author "Grosso F."
649 results on '"Grosso F."'

2. Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma

Author

Cortinovis, D., Canova, S., Colonese, F., Abbate, M.I., Sala, L., Sala, E., Perez Gila, M., Bono, F., Pagni, F., Ceresoli, G.L., D’Aveni, A., Bonomi, M., Grosso, F., De Angelis, A., Ugo, F., Belletti, M., Zucali, P.A., Perrino, M., De Vincenzo, F., Santoro, A., Gelsomino, F., Ardizzoni, A., Pasello, G., Frega, S., Mencoboni, M., Carlucci, L., De Simone, I., D’Incalci, M., Galli, F., Poli, D., Rulli, E., Torri, V., and Cortinovis, D.L.

Published
2022
Full Text
View/download PDF

7. Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma

Author

Szlosarek, P, Creelan, B, Sarkodie, T, Nolan, L, Taylor, P, Olevsky, O, Grosso, F, Cortinovis, D, Chitnis, M, Roy, A, Gilligan, D, Kindler, H, Papadatos-Pastos, D, Ceresoli, G, Mansfield, A, Tsao, A, O’Byrne, K, Nowak, A, Steele, J, Sheaff, M, Shiu, C, Kuo, C, Johnston, A, Bomalaski, J, Zauderer, M, Fennell, D, Rybkin, I, Rolfo, C, Mackean, M, Steele, N, Franks, K, Shaw, P, Lind, M, Upadhyay, S, John, T, Karapetis, C, Srivastav, R, Mencoboni, M, Chella, A, Zilembo, N, de Marinis, F, Stella, M, Chong, I, Wang, C, Null, N, Szlosarek, Peter W., Creelan, Benjamin C., Sarkodie, Thomas, Nolan, Luke, Taylor, Paul, Olevsky, Olga, Grosso, Federica, Cortinovis, Diego, Chitnis, Meenali, Roy, Amy, Gilligan, David, Kindler, Hedy, Papadatos-Pastos, Dionysis, Ceresoli, Giovanni L., Mansfield, Aaron S., Tsao, Anne, O’Byrne, Kenneth J., Nowak, Anna K., Steele, Jeremy, Sheaff, Michael, Shiu, Chiung-Fang, Kuo, Chih-Ling, Johnston, Amanda, Bomalaski, John, Zauderer, Marjorie G., Fennell, Dean A., Rybkin, Igor I., Rolfo, Christian D., MacKean, Melanie, Steele, Nicola, Franks, Kevin, Shaw, Paul, Lind, Michael J., Upadhyay, Sunil, John, Thomas, Karapetis, Christos, Srivastav, Ratnesh, Mencoboni, Manlio, Chella, Antonio, Zilembo, Nicoletta, de Marinis, Filippo, Stella, Maria Giulia, Chong, Inn-Wen, Wang, Chin-Chou, null, null, Szlosarek, P, Creelan, B, Sarkodie, T, Nolan, L, Taylor, P, Olevsky, O, Grosso, F, Cortinovis, D, Chitnis, M, Roy, A, Gilligan, D, Kindler, H, Papadatos-Pastos, D, Ceresoli, G, Mansfield, A, Tsao, A, O’Byrne, K, Nowak, A, Steele, J, Sheaff, M, Shiu, C, Kuo, C, Johnston, A, Bomalaski, J, Zauderer, M, Fennell, D, Rybkin, I, Rolfo, C, Mackean, M, Steele, N, Franks, K, Shaw, P, Lind, M, Upadhyay, S, John, T, Karapetis, C, Srivastav, R, Mencoboni, M, Chella, A, Zilembo, N, de Marinis, F, Stella, M, Chong, I, Wang, C, Null, N, Szlosarek, Peter W., Creelan, Benjamin C., Sarkodie, Thomas, Nolan, Luke, Taylor, Paul, Olevsky, Olga, Grosso, Federica, Cortinovis, Diego, Chitnis, Meenali, Roy, Amy, Gilligan, David, Kindler, Hedy, Papadatos-Pastos, Dionysis, Ceresoli, Giovanni L., Mansfield, Aaron S., Tsao, Anne, O’Byrne, Kenneth J., Nowak, Anna K., Steele, Jeremy, Sheaff, Michael, Shiu, Chiung-Fang, Kuo, Chih-Ling, Johnston, Amanda, Bomalaski, John, Zauderer, Marjorie G., Fennell, Dean A., Rybkin, Igor I., Rolfo, Christian D., MacKean, Melanie, Steele, Nicola, Franks, Kevin, Shaw, Paul, Lind, Michael J., Upadhyay, Sunil, John, Thomas, Karapetis, Christos, Srivastav, Ratnesh, Mencoboni, Manlio, Chella, Antonio, Zilembo, Nicoletta, de Marinis, Filippo, Stella, Maria Giulia, Chong, Inn-Wen, Wang, Chin-Chou, and null, null

Abstract

IMPORTANCE Arginine deprivation using ADI-PEG20 (pegargiminase) combined with chemotherapy is untested in a randomized study among patients with cancer. ATOMIC-Meso (ADI-PEG20 Targeting of Malignancies Induces Cytotoxicity-Mesothelioma) is a pivotal trial comparing standard first-line chemotherapy plus pegargiminase or placebo in patients with nonepithelioid pleural mesothelioma. OBJECTIVE To determine the effect of pegargiminase-based chemotherapy on survival in nonepithelioid pleural mesothelioma, an arginine-auxotrophic tumor. DESIGN, SETTING, AND PARTICIPANTS Thiswas a phase 2-3, double-blind randomized clinical trial conducted at 43 centers in 5 countries that included patients with chemotherapy-naive nonepithelioid pleural mesothelioma from August 1, 2017, to August 15, 2021, with at least 12 months' follow-up. Final follow-up was on August 15, 2022. Data analysis was performed from March 2018 to June 2023. INTERVENTION Patients were randomly assigned (1:1) to receive weekly intramuscular pegargiminase (36.8mg/m2) or placebo. All patients received intravenous pemetrexed (500mg/m2) and platinum (75-mg/m2 cisplatin or carboplatin area under the curve 5) chemotherapy every 3 weeks up to 6 cycles. Pegargiminase or placebo was continued until progression, toxicity, or 24 months. MAIN OUTCOMES AND MEASURES The primary end pointwas overall survival, and secondary end points were progression-free survival and safety. Response rate by blinded independent central review was assessed in the phase 2 portion only. RESULTS Among 249 randomized patients (mean [SD] age, 69.5 [7.9] years; 43 female individuals [17.3%] and 206 male individuals [82.7%]), all were included in the analysis. The median overall survival was 9.3 months (95%CI, 7.9-11.8 months) with pegargiminase-chemotherapy as compared with 7.7 months (95%CI, 6.1-9.5 months) with placebo-chemotherapy (hazard ratio [HR] for death, 0.71; 95%CI, 0.55-0.93; P = .02). The median progression-free survival was 6.2 months (

Published
2024

9. Standardising black soldier fly larvae feeding experiments: an initial protocol and variability estimates

Author

Deruytter, D., primary, Gasco, L., additional, Yakti, W., additional, Katz, H., additional, Coudron, C.L., additional, Gligorescu, A., additional, Frooninckx, L., additional, Noyens, I., additional, Meneguz, M., additional, Grosso, F., additional, Bellezza Oddon, S., additional, Biasato, I., additional, Mielenz, M., additional, Veldkamp, T., additional, Van Loon, J.J.A., additional, Spranghers, T., additional, Vandenberg, G.W., additional, Oonincx, D.G.A.B., additional, and Bosch, G., additional

Published
2023
Full Text
View/download PDF

10. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial

Author

Cipolla, C.M., Cardinale, D., Ciceri, F., Latini, R., Sandri, M.T., Maggioni, A.P., Labianca, R., Tettamanti, M., Senni, M., Finzi, A., Grosso, F., Vago, T., Civelli, M., Gramenzi, S., Masson, S., Balconi, G., Bernasconi, R., Salvatici, M., Nicolis, E., Barlera, S., Magnoli, M., Buratti, M.G., Ojeda Fernandez, M.L., Franzosi, M.G., Staszewsky, L., Vasamì, A., Malossi, A., Sicuro, M., Thiebat, B., Barè, C., Corzani, A., Coccolo, F., Colecchia, S., Pellegrini, C., Bregni, M., Appio, L., Caico, I., G.Rossetti, Mesenzani, O., Campana, C., Giordano, M., Gilardoni, M., Scognamiglio, G., Corrado, G., Battagin, D., De Rosa, F., Carpino, C., Palazzo, S., Monopoli, A., Milandri, C., Giannessi, P.G., Zipoli, G., Ghisoni, F., Rizzo, A., Pastori, P., Callegari, S., Sesenna, C., Colombo, A., G.Curigliano, Fodor, C., Mangiavacchi, M., Cavina, R., Guiducci, D., Mazza, R., Turazza, F.M., Vallerio, P., Marbello, L., Sala, E., Fragasso, G., Trinca, S., Aquilina, M., Rocca, A., Farolfi, A., Andreis, D., Gori, S., Barbieri, E., Lanzoni, L., Marchetti, F., Falci, C., Bianchi, A., Mioranza, E., Banzato, A., Re, F., Gaibazzi, N., Gullo, M., Turina, M.C., Gervasi, E., Giaroli, F., Nassiacos, D., Verusio, C., Barco, B., Bertolini, A., Cucchi, G., Menatti, E., Sinagra, G., Aleksova, A., Guglielmi, A., Pinotti, G., Gueli, R., Mongiardi, C., Vallini, I., Cardinale, Daniela, Ciceri, Fabio, Latini, Roberto, Franzosi, Maria Grazia, Sandri, Maria Teresa, Civelli, Maurizio, Cucchi, GianFranco, Menatti, Elisabetta, Mangiavacchi, Maurizio, Cavina, Raffaele, Barbieri, Enrico, Gori, Stefania, Colombo, Alessandro, Curigliano, Giuseppe, Salvatici, Michela, Rizzo, Antonio, Ghisoni, Francesco, Bianchi, Alessandra, Falci, Cristina, Aquilina, Michele, Rocca, Andrea, Monopoli, Anna, Milandri, Carlo, Rossetti, Giuseppe, Bregni, Marco, Sicuro, Marco, Malossi, Alessandra, Nassiacos, Daniele, Verusio, Claudio, Giordano, Monica, Staszewsky, Lidia, Barlera, Simona, Nicolis, Enrico B., Magnoli, Michela, Masson, Serge, and Cipolla, Carlo M.

Published
2018
Full Text
View/download PDF

12. Transcription regulators and ultra-rare and other rare translocation-related sarcomas treated with trabectedin: A proof of principle from a post-hoc analysis

Author

Palmerini E., Sanfilippo R., Grignani G., Buonadonna A., Romanini A., Badalamenti G., Ferraresi V., Vincenzi B., Comandone A., Pizzolorusso A., Brunello A., Gelsomino F., De Pas T., Ibrahim T., Gurrieri L., Grosso F., Zanelli F., Pantaleo M. A., Milesi L., Ciuffreda L., Ferrari V., Marchesi E., Quattrini I., Righi A., Setola E., Carretta E., Casali P. G., Picci P., Ferrari S., Palmerini E., Sanfilippo R., Grignani G., Buonadonna A., Romanini A., Badalamenti G., Ferraresi V., Vincenzi B., Comandone A., Pizzolorusso A., Brunello A., Gelsomino F., De Pas T., Ibrahim T., Gurrieri L., Grosso F., Zanelli F., Pantaleo M.A., Milesi L., Ciuffreda L., Ferrari V., Marchesi E., Quattrini I., Righi A., Setola E., Carretta E., Casali P.G., Picci P., and Ferrari S.

Subjects
Cancer Research, sarcoma, ultra-rare, Oncology, translocation-related, soft tissue, rare
Abstract

BackgroundAmong sarcomas, which are rare cancers with an incidence of Cancers 2021; ClinicalTrials.gov Identifier: NCT02793050).MethodsA post-hoc analysis of case series to evaluate the efficacy and safety of trabectedin on patients with ultra-rare and other rare translocation-related sarcomas included in TrObs study was performed. Main outcomes comprised investigator-assessed overall response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and safety.ResultsThirty-six patients (18 women) with ultra-rare and other rare sarcoma and a median age of 53.0 years (range: 22-81) were included. Most patients had solitary fibrous tumor (SFT; n=11) followed by epithelioid sarcoma (n=5), malignant peripheral nerve sheath tumor (MPNST; n=4), extraskeletal myxoid chondrosarcoma (EMC; n=3), desmoplastic small round cell tumor (DSRCT; n=3), and alveolar soft part sarcoma (ASPS), rhabdomyosarcoma and clear cell sarcoma (n=2 each). Thirty-five patients had metastatic disease and 23 patients received trabectedin as a second-line treatment. Among 35 patients evaluable for response, two patients with SFT and ASPS had a partial response and one patient with DSRCT obtained a complete response, reaching an ORR of 8.6% (95% CI: 2.8-23.4%). Among patients with an ORR, 6-months PFS was 100% in patients with ASPS, 45.7% in patients with SFT and 33.3% in those with DSRCT. Two patients with epithelioid sarcoma and myoepithelioma had disease stabilization lasting >24 months. Nine patients had at least one grade 3/4 adverse event, mostly being bone marrow toxicity (n=6).ConclusionsTrabectedin has some anti-tumor activity in some ultra-rare and other rare sarcomas, particularly translocation-related sarcomas, with the well-known manageable safety profile.

Published
2022
Full Text
View/download PDF

13. Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma

Author

Canova, S, Ceresoli, G, Grosso, F, Zucali, P, Gelsomino, F, Pasello, G, Mencoboni, M, Rulli, E, Galli, F, De Simone, I, Carlucci, L, De Angelis, A, Belletti, M, Bonomi, M, D'Aveni, A, Perrino, M, Bono, F, Cortinovis, D, Colonese, F, Abbate, M, Sala, L, Sala, E, Perez Gila, M, Pagni, F, Ugo, F, De Vincenzo, F, Santoro, A, Ardizzoni, A, Frega, S, D'Incalci, M, Poli, D, Torri, V, Canova S., Ceresoli G. L., Grosso F., Zucali P. A., Gelsomino F., Pasello G., Mencoboni M., Rulli E., Galli F., De Simone I., Carlucci L., De Angelis A., Belletti M., Bonomi M., D'Aveni A., Perrino M., Bono F., Cortinovis D. L., Cortinovis D., Colonese F., Abbate M. I., Sala L., Sala E., Perez Gila M., Pagni F., Ugo F., De Vincenzo F., Santoro A., Ardizzoni A., Frega S., D'Incalci M., Poli D., Torri V., Canova, S, Ceresoli, G, Grosso, F, Zucali, P, Gelsomino, F, Pasello, G, Mencoboni, M, Rulli, E, Galli, F, De Simone, I, Carlucci, L, De Angelis, A, Belletti, M, Bonomi, M, D'Aveni, A, Perrino, M, Bono, F, Cortinovis, D, Colonese, F, Abbate, M, Sala, L, Sala, E, Perez Gila, M, Pagni, F, Ugo, F, De Vincenzo, F, Santoro, A, Ardizzoni, A, Frega, S, D'Incalci, M, Poli, D, Torri, V, Canova S., Ceresoli G. L., Grosso F., Zucali P. A., Gelsomino F., Pasello G., Mencoboni M., Rulli E., Galli F., De Simone I., Carlucci L., De Angelis A., Belletti M., Bonomi M., D'Aveni A., Perrino M., Bono F., Cortinovis D. L., Cortinovis D., Colonese F., Abbate M. I., Sala L., Sala E., Perez Gila M., Pagni F., Ugo F., De Vincenzo F., Santoro A., Ardizzoni A., Frega S., D'Incalci M., Poli D., and Torri V.

Abstract

Background: Malignant pleural mesothelioma (MPM) is a cancer with a high mortality rate and few therapeutic options. After platinum–pemetrexed combination, no further promising drug seems to be effective. Immune checkpoint inhibitors may have some activity in pretreated patients and no data are available in this population about durvalumab. Materials and methods: DIADEM was a multicenter, open-label, single-arm, phase II trial aimed at evaluating the efficacy and safety of durvalumab. Patients with locally advanced/metastatic MPM who progressed after platinum–pemetrexed chemotherapy were enrolled to receive durvalumab (1500 mg, intravenously Q4W) for 12 months or until evidence of disease progression or unacceptable toxicity. The primary endpoint was the proportion of patients alive and free from progression at 16 weeks (PFS16wks) calculated from treatment initiation. Secondary endpoints were progression-free survival, overall survival, overall response rate, and safety. Results: Sixty-nine patients with a median age of 69 years (range 44-82 years) were enrolled; 62 patients (89.9%) had epithelioid histotype. As first-line treatment, all patients received platinum derivatives–pemetrexed combination (60.9% with carboplatin and 39.1% with cisplatin). As of March 2021, the median follow-up was 9.2 months (interquartile range 5.2-11.1 months). Six patients (8.7%) completed the 12-month treatment; 60 patients discontinued, of whom 42 for progressive disease, and 4 died. Seventeen patients (28.3%; 95% confidence interval 17.5% to 41.4%) were alive or free from progression at 16 weeks. Eleven patients (18.6%) had a grade 3 or 4 treatment-related adverse event (AE), and one (1.4%) had a grade ≥3 immune-related, treatment-related AE. There was one drug-related death. Conclusion: Durvalumab alone in pretreated non-selected MPM did not reach a meaningful clinical activity, showing any new major safety issue signals.

Published
2022

14. Placebo and Nocebo Effects as Bayesian-Brain Phenomena: The Overlooked Role of Likelihood and Attention

Author

Pagnini, Francesco, Barbiani, Diletta, Cavalera, Cesare Massimo, Volpato, Eleonora, Grosso, Francesca, Minazzi, Giacomo Andrea, Vailati Riboni, Francesco Carlo Paolo, Graziano, F., Di Tella, Sonia, Manzoni, Gian Mauro, Silveri, Maria Caterina, Riva, Giuseppe, Phillips, Deborah, Pagnini F. (ORCID:0000-0003-1612-4211), Barbiani D., Cavalera C. (ORCID:0000-0001-9309-0874), Volpato E. (ORCID:0000-0003-0266-6386), Grosso F. (ORCID:0000-0001-5232-8313), Minazzi G. A. (ORCID:0000-0003-1262-0701), Vailati Riboni F., Di Tella S. (ORCID:0000-0002-2248-5120), Manzoni G. M., Silveri M. C. (ORCID:0000-0001-5012-0682), Riva G. (ORCID:0000-0003-3657-106X), Phillips D., Pagnini, Francesco, Barbiani, Diletta, Cavalera, Cesare Massimo, Volpato, Eleonora, Grosso, Francesca, Minazzi, Giacomo Andrea, Vailati Riboni, Francesco Carlo Paolo, Graziano, F., Di Tella, Sonia, Manzoni, Gian Mauro, Silveri, Maria Caterina, Riva, Giuseppe, Phillips, Deborah, Pagnini F. (ORCID:0000-0003-1612-4211), Barbiani D., Cavalera C. (ORCID:0000-0001-9309-0874), Volpato E. (ORCID:0000-0003-0266-6386), Grosso F. (ORCID:0000-0001-5232-8313), Minazzi G. A. (ORCID:0000-0003-1262-0701), Vailati Riboni F., Di Tella S. (ORCID:0000-0002-2248-5120), Manzoni G. M., Silveri M. C. (ORCID:0000-0001-5012-0682), Riva G. (ORCID:0000-0003-3657-106X), and Phillips D.

Abstract

The Bayesian-brain framework applied to placebo responses and other mind-body interactions suggests that the effects on the body result from the interaction between priors, such as expectations and learning, and likelihood, such as somatosensorial information. Significant research in this area focuses on the role of the priors, but the relevance of the likelihood has been surprisingly overlooked. One way of manipulating the relevance of the likelihood is by paying attention to sensorial information. We suggest that attention can influence both precision and position (i.e., the relative distance from the priors) of the likelihood by focusing on specific components of the somatosensorial information. Two forms of attention seem particularly relevant in this framework: mindful attention and selective attention. Attention has the potential to be considered a "major player" in placebo/nocebo research, together with expectations and learning. In terms of application, relying on attentional strategies as "amplifiers" or "silencers" of sensorial information could lead to an active involvement of individuals in shaping their care process and health. In this contribution, we discuss the theoretical implications of these intuitions with the aim to provide a comprehensive framework that includes Bayesian brain, placebo/nocebo effects, and the role of attention in mind-body interactions.

Published
2023

15. Standardising black soldier fly larvae feeding experiments: an initial protocol and variability estimates

Author

Deruytter, David, Gasco, Laura, Yakti, W., Katz, H., Coudron, C.L., Glirorescu, A., Frooninckx, L., Noyens, I., Meneguz, Marco, Grosso, F., Bellezza Oddon, S., Biasato, I., Mielenz, M., Veldkamp, T., van Loon, J.J.A., Spranghers, Thomas, Vandenberg, G., Oonincx, D.G.A.B., Bosch, G., Deruytter, David, Gasco, Laura, Yakti, W., Katz, H., Coudron, C.L., Glirorescu, A., Frooninckx, L., Noyens, I., Meneguz, Marco, Grosso, F., Bellezza Oddon, S., Biasato, I., Mielenz, M., Veldkamp, T., van Loon, J.J.A., Spranghers, Thomas, Vandenberg, G., Oonincx, D.G.A.B., and Bosch, G.

Abstract

There is a growing interest in the ability of black soldier fly (Hermetia illucens) larvae (BSFL) to convert low-value organic residues into high-value products. This leads to more publications with conversion data for various organic resources. However, these results are rarely comparable between laboratories due to differences in study protocols. This hinders comparisons among studies, the use of results in practice, and overall advancement in BSFL conversion research. Therefore, a standardised research protocol was developed for nursing, rearing and harvesting of BSFL for feed assessment. The utility of this protocol, was assessed via an international ring test with 9 partners. One batch of Gainesville diet (wheat bran (50%), alfa-alfa (30%) and maize (20%)) was produced and distributed among the partners to avoid dietary variations. Five-day-old BSFL larvae were used for the growth trial with six replicates per partner. Average larval weight was assessed after 3 days, 7 days, and harvest (>10% prepupae). Total yield and frass were recorded, and samples were chemically analysed to allow the quantification of the conversion efficiency. The results were used to calculate the within and between partner variability of the protocol. The results indicate that for the biological parameters (average weight, yield and density) the within partner variability was 24% and the between partner variability was 60%. For the assessed chemical parameters (N, fat, ash, P, K, pH), both the within and between variability was lower (respectively 9 and 28%). The results of this study give a first indication of the variability that can be expected within and between BSFL feeding experiments for different parameters and can therefore serve as guideline when developing a new experimental designs, assess standard operating procedures and other applications. The protocol can be used as first basis for future feed experiments, improving the comparability of results.

Published
2023

16. Development of the Capability Index and Assessment of Sustainable Employability Network Associations

Author

Picco, E, Costantini, G, Grosso, F, Calicchia, S, Colagiacomo, C, Pistagni, R, Manco, C, Badellino, E, Papaleo, B, Signorini, S, Miglioretti, M, Eleonora Picco, Giulio Costantini, Francesca Grosso, Sara Calicchia, Chiara Colagiacomo, Roberta Pistagni, Chiara Manco, Elisabetta Badellino, Bruno Papaleo, Stefano Signorini, Massimo Miglioretti, Picco, E, Costantini, G, Grosso, F, Calicchia, S, Colagiacomo, C, Pistagni, R, Manco, C, Badellino, E, Papaleo, B, Signorini, S, Miglioretti, M, Eleonora Picco, Giulio Costantini, Francesca Grosso, Sara Calicchia, Chiara Colagiacomo, Roberta Pistagni, Chiara Manco, Elisabetta Badellino, Bruno Papaleo, Stefano Signorini, and Massimo Miglioretti

Published
2023

17. CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma

Author

Betti, M., Aspesi, A., Biasi, A., Casalone, E., Ferrante, D., Ogliara, P., Gironi, L.C., Giorgione, R., Farinelli, P., Grosso, F., Libener, R., Rosato, S., Turchetti, D., Maffè, A., Casadio, C., Ascoli, V., Dianzani, C., Colombo, E., Piccolini, E., Pavesi, M., Miccoli, S., Mirabelli, D., Bracco, C., Righi, L., Boldorini, R., Papotti, M., Matullo, G., Magnani, C., Pasini, B., and Dianzani, I.

Published
2016
Full Text
View/download PDF

18. Insights into the phylogeny, resistome, virulome and host adaptation from Gardnerella genome analysis

Author

Teixeira, P., Sousa, M., Grosso, F., Ribeiro, T., and Peixe, L.

Abstract

Background: Gardnerella spp. is often seen as evidence of vaginal pathologies, although members of this genus can also be found in the urinary and vaginal microbiota of asymptomatic women [1,2], making its role in the urogenital tract unclear. Objective: To assess phylogenomic and functional analysis of Gardnerella genus. Resistance (ARGs) and virulence genes (Vg) was also explored to unveil their role in health and urogenital disease development. Methods:Twenty-nine Gardnerella isolates from urine (U, n=22) and vaginal swabs (VSn=7) of women [24 asymptomatic, 5 with overactive bladder (OAB)] were identified by cpn60 and WGS (NovaSeq 6000; Illumina). Together with118 genomes from public databases (from U (n=35), VS (n=82) blood (n=1), and unknown samples (n=2)), we used TYGS platform and fastANI for species identification. Phylogenomic and pangenome analyses were performed using anvi’o v7.1 and Roary. Vg were annotated with COG and KEGG databases, and ARGs with AMRFinder Plus. Vg presence/absence outoputs were analyzed with R. Results: 4 species and 10 genomic species were identified, 41% of the collection being comprised by G. vaginalis. ANI and dDDH values are insufficient for distinguishing Gardnerella species. Pangenome was composed by4537 gene clusters and the core genome of by 514. Differences in carbohydrates and amino acid metabolism and absence of correlation of functions with human body sites or disease were observed. The virulome and Gardnerellaspecies/genomospecies exhibit are intertwined. ARG to aminoglycosides (aph(3')-Ia), macrolides (mefA, msrD, ermX), tetracyclines (tetM, tetL), lincosamide and streptogramins (lsaC) were detected in several isolates. Open pangenomes were observed in G. vaginalis, G. leopoldii, G. swidsinskii and GG3. Conclusions: Gardnerella comprises 4 species and 10 genomic species. Core genome analysis, ANI and dDDH are recommended for appropriate species assignment. Gardnerella species/genomospecies are associated with a particular set of VFs and metabolic functions. ARGs with clinical relevance were also observed in different Gardnerella species., Scientific Letters, Vol. 1 No. Sup 1 (2023)

Published
2023
Full Text
View/download PDF

19. Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma

Author

Canova, S., primary, Ceresoli, G.L., additional, Grosso, F., additional, Zucali, P.A., additional, Gelsomino, F., additional, Pasello, G., additional, Mencoboni, M., additional, Rulli, E., additional, Galli, F., additional, De Simone, I., additional, Carlucci, L., additional, De Angelis, A., additional, Belletti, M., additional, Bonomi, M., additional, D’Aveni, A., additional, Perrino, M., additional, Bono, F., additional, Cortinovis, D.L., additional, Cortinovis, D., additional, Canova, S., additional, Colonese, F., additional, Abbate, M.I., additional, Sala, L., additional, Sala, E., additional, Perez Gila, M., additional, Pagni, F., additional, Ugo, F., additional, De Vincenzo, F., additional, Santoro, A., additional, Ardizzoni, A., additional, Frega, S., additional, D’Incalci, M., additional, Poli, D., additional, and Torri, V., additional

Published
2022
Full Text
View/download PDF

20. One year after on Tyrrhenian coasts: The ban of cotton buds does not reduce their dominance in beach litter composition

Author

Poeta, G., primary, Bazzichetto, M., additional, Gallitelli, L., additional, Garzia, M., additional, Aprea, F., additional, Bartoli, F., additional, Battisti, C., additional, Cascone, S., additional, Corradi, A., additional, D’Amelia, D., additional, D’Amico, E., additional, De Luca, J., additional, Del Grosso, F., additional, Iacobelli, L., additional, Langone, S., additional, Lembo Fazio, C., additional, Locchi, G., additional, Perrone, M., additional, Petroni, F., additional, Raimondi, D., additional, Romiti, F., additional, Secco, S., additional, Sonet, L., additional, Spinelli, A., additional, Toscano, S., additional, Vanadia, S., additional, Vecchi, S., additional, Zanon, F., additional, and Malavasi, M., additional

Published
2022
Full Text
View/download PDF

22. EP07.01-004 Long Survivor Epithelioid Pleural Mesotheliomas Are Characterized by Tertiary Lymphoid Structures: An Update to the MATCH Study

Author

Grosso, F., primary, Mannarino, L., additional, Paracchini, L., additional, Pezzuto, F., additional, Moracci, L., additional, Olteanu, G.-E., additional, Delfanti, S., additional, Callari, M., additional, Penpa, S., additional, Maconi, A., additional, De Simone, I., additional, Bosetti, C., additional, Allavena, P., additional, Marchini, S., additional, Calabrese, F., additional, and D'Incalci, M., additional

Published
2022
Full Text
View/download PDF

25. Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study

Author

Cortinovis, D, Grosso, F, Carlucci, L, Zucali, P, Pasello, G, Tiseo, M, Sperandi, F, Hollander, L, Galli, F, Torri, V, Rulli, E, Canova, S, Maconi, A, Bidoli, P, Ceresoli, G, D'Incalci, M, Cortinovis D., Grosso F., Carlucci L., Zucali P. A., Pasello G., Tiseo M., Sperandi F., Hollander L., Galli F., Torri V., Rulli E., Canova S., Maconi A., Bidoli P., Ceresoli G. L., D'Incalci M., Cortinovis, D, Grosso, F, Carlucci, L, Zucali, P, Pasello, G, Tiseo, M, Sperandi, F, Hollander, L, Galli, F, Torri, V, Rulli, E, Canova, S, Maconi, A, Bidoli, P, Ceresoli, G, D'Incalci, M, Cortinovis D., Grosso F., Carlucci L., Zucali P. A., Pasello G., Tiseo M., Sperandi F., Hollander L., Galli F., Torri V., Rulli E., Canova S., Maconi A., Bidoli P., Ceresoli G. L., and D'Incalci M.

Abstract

ATREUS was a phase II, single arm, multicenter study aimed at exploring the activity and safety of trabectedin in 78 epithelioid patients and 67 nonepithelioid patients with unresectable malignant pleural mesothelioma. Trabectedin showed modest clinical activity, at the expense of relevant liver toxicity. Introduction: New therapeutic approaches in unresectable malignant pleural mesothelioma (MPM) are eagerly awaited. Trabectedin is an antitumor agent with an effect on cancer cell proliferation and a modulating action on tumor microenvironment. The ATREUS study explored the activity and safety of trabectedin in patients with unresectable MPM. Methods: Epithelioid patients with MPM received trabectedin as second-line while biphasic/sarcomatoid patients with MPM as first- or second-line therapy. Treatment was given intravenously at an initially planned dose of 1.3 mg/m(2) every 3 weeks, until progression or unacceptable toxicity. The primary endpoint was progression-free survival rate at 12 weeks (PFS12wks). Results: Overall, 78 patients (54%) had epithelioid and 67 (46%) nonepithelioid MPM. PFS12wks in 62 evaluable patients with epithelioid MPM was 43.5% (80% confidence interval 34.9%-52.5%); median progression-free and overall survival were 2.4 and 9.0 months, respectively. PFS12wks in 52 evaluable patients with nonepithelioid MPM was 30.8% (90% confidence interval 20.3%-42.9%); median progression-free and overall survival were 1.7 and 5.4 months. Trabectedin starting dose was amended due to excess of liver toxicity. Eighty-four (64%) and 48 (36%) patients received 1.3 mg/m(2 )and 1.1. mg/m(2), respectively. The most common grade 3-4 toxicities were hepatotoxicity, leukopenia/neutropenia, and fatigue. Grade 3-4 hepatotoxicity was reported in 59 (70%) patients treated at 1.3 mg/m(2), and in 19 (40%) treated at 1.1 mg/m(2). Conclusions: Trabectedin showed modest clinical activity, at the expense of relevant liver toxicity. Further development of this drug in MPM at fu

Published
2021

26. MICRORNA-197-3P UP-REGULATION IN SERA AND CELLS FROM MALIGNANT PLEURAL MESOTHELIOMA AFFECTED PATIENTS

Author

BONONI, I., primary, TOGNON, M., additional, DI MAURO, G., additional, FRONTINI, F., additional, OTON-GONZALEZ, L., additional, TORREGGIANI, E., additional, IAQUINTA, M.R., additional, MAZZIOTTA, C., additional, MAZZONI, E., additional, STENDARDO, M.R., additional, BOSCHETTO, P., additional, LIBENER, R., additional, GUASCHINO, R., additional, GROSSO, F., additional, and MARTINI, F., additional

Published
2022
Full Text
View/download PDF

27. Sustainable employability to innovate the organization of work

Author

Grosso, F, Colagiacomo, C, Pistagni, R, Calicchia, S, Signorini, S, Papaleo, B, Miglioretti, M, Picco, E, Manco, C, Francesca Grosso, Chiara Colagiacomo, Roberta Pistagni, Sara Calicchia, Stefano Signorini, Bruno Papaleo, Massimo Miglioretti, Eleonora Picco, Chiara Manco, Grosso, F, Colagiacomo, C, Pistagni, R, Calicchia, S, Signorini, S, Papaleo, B, Miglioretti, M, Picco, E, Manco, C, Francesca Grosso, Chiara Colagiacomo, Roberta Pistagni, Sara Calicchia, Stefano Signorini, Bruno Papaleo, Massimo Miglioretti, Eleonora Picco, and Chiara Manco

Published
2022

28. Occupabilità sostenibile: un contributo all’ergonomia organizzativa

Author

Bellandi, T, Frangioni, G, Pistagni, R, Calicchia, S, Picco, E, Grosso, F, Colagiacomo, C, Manco, C, Miglioretti, M, Signorini, S, Papaleo, B, Roberta Pistagni, Sara Calicchia, Eleonora Picco, Francesca Grosso, Chiara Colagiacomo, Chiara Manco, Massimo Miglioretti, Stefano Signorini, Bruno Papaleo, Bellandi, T, Frangioni, G, Pistagni, R, Calicchia, S, Picco, E, Grosso, F, Colagiacomo, C, Manco, C, Miglioretti, M, Signorini, S, Papaleo, B, Roberta Pistagni, Sara Calicchia, Eleonora Picco, Francesca Grosso, Chiara Colagiacomo, Chiara Manco, Massimo Miglioretti, Stefano Signorini, and Bruno Papaleo

Published
2022

29. Participatory methods in intervention research: a case study in Italy

Author

Calicchia, S, Pistagni, R, Grosso, F, Colagiacomo, C, Picco, E, Manco, C, Miglioretti, M, Signorini, S, Papaleo, B, Sara Calicchia, Roberta Pistagni, Francesca Grosso, Chiara Colagiacomo, Eleonora Picco, Chiara Manco, Massimo Miglioretti, Stefano Signorini, Bruno Papaleo, Calicchia, S, Pistagni, R, Grosso, F, Colagiacomo, C, Picco, E, Manco, C, Miglioretti, M, Signorini, S, Papaleo, B, Sara Calicchia, Roberta Pistagni, Francesca Grosso, Chiara Colagiacomo, Eleonora Picco, Chiara Manco, Massimo Miglioretti, Stefano Signorini, and Bruno Papaleo

Published
2022

30. Intervention and participatory research through coaching and facilitation

Author

Pistagni, R, Calicchia, S, Grosso, F, Colagiacomo, C, Picco, E, Manco, C, Miglioretti, M, Signorini, S, Papaleo, B, Roberta Pistagni, Sara Calicchia, Francesca Grosso, Chiara Colagiacomo, Eleonora Picco, Chiara Manco, Massimo Miglioretti, Stefano Signorini, Bruno Papaleo, Pistagni, R, Calicchia, S, Grosso, F, Colagiacomo, C, Picco, E, Manco, C, Miglioretti, M, Signorini, S, Papaleo, B, Roberta Pistagni, Sara Calicchia, Francesca Grosso, Chiara Colagiacomo, Eleonora Picco, Chiara Manco, Massimo Miglioretti, Stefano Signorini, and Bruno Papaleo

Published
2022

31. One year after on Tyrrhenian coasts: The ban of cotton buds does not reduce their dominance in beach litter composition

Author

Poeta, G., Bazzichetto, Manuele, Gallitelli, L., Garzia, M., Aprea, F., Bartoli, F., Battisti, C., Cascone, Silvia, Corradi, A., D’Amelia, D., D’Amico, E., Luca, J. De, Grosso, F. Del, Iacobelli, L., Langone, S., Lembo Fazio, C., Locchi, G., Perrone, M., Petroni, F., Raimondi, D., Romiti, F., Secco, S., Sonet, L., Spinelli, A., Toscano, S., Vanadia, S., Vecchi, S., Zanon, F., Malavasi, Marco, Poeta, G., Bazzichetto, Manuele, Gallitelli, L., Garzia, M., Aprea, F., Bartoli, F., Battisti, C., Cascone, Silvia, Corradi, A., D’Amelia, D., D’Amico, E., Luca, J. De, Grosso, F. Del, Iacobelli, L., Langone, S., Lembo Fazio, C., Locchi, G., Perrone, M., Petroni, F., Raimondi, D., Romiti, F., Secco, S., Sonet, L., Spinelli, A., Toscano, S., Vanadia, S., Vecchi, S., Zanon, F., and Malavasi, Marco

Abstract

In January 2019, Italy banned the sale of plastic cotton buds, which is one of the most abundant litter items entering the sea and then washing ashore. However, since the ban came into force, no studies have been carried out to assess whether the measure has actually led to the reduction of plastic cotton buds accumulating on Italian coasts. Here we aim at evaluating the effectiveness of the ban in reducing the amount of cotton buds reaching sandy beaches of the Tyrrhenian coast. Specifically, we monitored the accumulation of beach litter for one year since the ban came into force. By surveying eight coastal sites from winter 2019 to winter 2020, we collected a total of 52,824 items mostly constituted by plastic debris (97.6%). We found that cotton buds were the most abundant item (42.3% of total litter), followed by plastic (28.5%) and polystyrene (5.43%) fragments. Our preliminary assessment suggests that the ban has so far not led to a sensible reduction in the amount of cotton buds entering the marine ecosystem. This was to be expected since implementation strategies are still lacking (i.e. no economic sanctions can be imposed in case of non-compliance) and bans are differently implemented among countries facing the Mediterranean Sea, calling for law enforcement and implementation at the national and international levels.

Published
2022

33. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

Author

Garassino, M.C., Whisenant, J.G., Huang, L.C., Trama, A., Torri, V., Agustoni, F., Baena, J., Banna, G., Berardi, R., Bettini, A.C., Bria, E., Brighenti, M., Cadranel, J., Toma, A. De, Chini, C., Cortellini, A., Felip, E., Finocchiaro, G., Garrido, P., Genova, C., Giusti, R., Gregorc, V., Grossi, F., Grosso, F., Intagliata, S., Verde, N. La, Liu, S.V., Mazieres, J., Mercadante, E., Michielin, O., Minuti, G., Moro-Sibilot, D., Pasello, G., Passaro, A., Scotti, V., Solli, P., Stroppa, E., Tiseo, M., Viscardi, G., Voltolini, L., Wu, Y.L., Zai, S., Pancaldi, V., Dingemans, A.M., Meerbeeck, J. Van, Barlesi, F., Wakelee, H., Schuurbiers, O.C.J., Peters, S., Horn, L., RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Pulmonologie, MUMC+: MA Med Staf Spec Longziekten (9), Pulmonary Medicine, TERAVOLT investigators, and TERAVOLT Investigators

Subjects
Male, 0301 basic medicine, medicine.medical_specialty, Aged, Betacoronavirus, Cause of Death, Coronavirus Infections, Cross-Sectional Studies, Female, Hospitalization, Humans, Longitudinal Studies, Middle Aged, Pandemics, Pneumonia, Viral, Registries, Risk Factors, Thoracic Neoplasms, COVID-19, Pneumonia, Viral, SARS-CoV-2, Article, 03 medical and health sciences, 0302 clinical medicine, Disease registry, Intensive care, Internal medicine, medicine, Medical history, Risk factor, Lung cancer, business.industry, Mortality rate, Cancer, Coronavirus Infections/epidemiology, Coronavirus Infections/mortality, Coronavirus Infections/pathology, Hospitalization/statistics & numerical data, Pneumonia, Viral/epidemiology, Pneumonia, Viral/mortality, Pneumonia, Viral/pathology, Registries/statistics & numerical data, Thoracic Neoplasms/epidemiology, Thoracic Neoplasms/mortality, Thoracic Neoplasms/pathology, Thoracic Neoplasms/therapy, medicine.disease, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Human medicine, business, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9], Cohort study
Abstract

Contains fulltext : 229846.pdf (Publisher’s version ) (Closed access) BACKGROUND: Early reports on patients with cancer and COVID-19 have suggested a high mortality rate compared with the general population. Patients with thoracic malignancies are thought to be particularly susceptible to COVID-19 given their older age, smoking habits, and pre-existing cardiopulmonary comorbidities, in addition to cancer treatments. We aimed to study the effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on patients with thoracic malignancies. METHODS: The Thoracic Cancers International COVID-19 Collaboration (TERAVOLT) registry is a multicentre observational study composed of a cross-sectional component and a longitudinal cohort component. Eligibility criteria were the presence of any thoracic cancer (non-small-cell lung cancer [NSCLC], small-cell lung cancer, mesothelioma, thymic epithelial tumours, and other pulmonary neuroendocrine neoplasms) and a COVID-19 diagnosis, either laboratory confirmed with RT-PCR, suspected with symptoms and contacts, or radiologically suspected cases with lung imaging features consistent with COVID-19 pneumonia and symptoms. Patients of any age, sex, histology, or stage were considered eligible, including those in active treatment and clinical follow-up. Clinical data were extracted from medical records of consecutive patients from Jan 1, 2020, and will be collected until the end of pandemic declared by WHO. Data on demographics, oncological history and comorbidities, COVID-19 diagnosis, and course of illness and clinical outcomes were collected. Associations between demographic or clinical characteristics and outcomes were measured with odds ratios (ORs) with 95% CIs using univariable and multivariable logistic regression, with sex, age, smoking status, hypertension, and chronic obstructive pulmonary disease included in multivariable analysis. This is a preliminary analysis of the first 200 patients. The registry continues to accept new sites and patient data. FINDINGS: Between March 26 and April 12, 2020, 200 patients with COVID-19 and thoracic cancers from eight countries were identified and included in the TERAVOLT registry; median age was 68.0 years (61.8-75.0) and the majority had an Eastern Cooperative Oncology Group performance status of 0-1 (142 [72%] of 196 patients), were current or former smokers (159 [81%] of 196), had non-small-cell lung cancer (151 [76%] of 200), and were on therapy at the time of COVID-19 diagnosis (147 [74%] of 199), with 112 (57%) of 197 on first-line treatment. 152 (76%) patients were hospitalised and 66 (33%) died. 13 (10%) of 134 patients who met criteria for ICU admission were admitted to ICU; the remaining 121 were hospitalised, but were not admitted to ICU. Univariable analyses revealed that being older than 65 years (OR 1.88, 95% 1.00-3.62), being a current or former smoker (4.24, 1.70-12.95), receiving treatment with chemotherapy alone (2.54, 1.09-6.11), and the presence of any comorbidities (2.65, 1.09-7.46) were associated with increased risk of death. However, in multivariable analysis, only smoking history (OR 3.18, 95% CI 1.11-9.06) was associated with increased risk of death. INTERPRETATION: With an ongoing global pandemic of COVID-19, our data suggest high mortality and low admission to intensive care in patients with thoracic cancer. Whether mortality could be reduced with treatment in intensive care remains to be determined. With improved cancer therapeutic options, access to intensive care should be discussed in a multidisciplinary setting based on cancer specific mortality and patients' preference. FUNDING: None.

Published
2020
Full Text
View/download PDF

34. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study

Author

Pinato, DJ, Aguilar-Company, J, Ferrante, D, Hanbury, G, Bower, M, Salazar, R, Mirallas, O, Sureda, A, Plaja, A, Cucurull, M, Mesia, R, Townsend, S, Jackson, A, Dalla Pria, A, Newsom-Davis, T, Handford, J, Sita-Lumsden, A, Apthorp, E, Vincenzi, B, Bertuzzi, A, Brunet, J, Lambertini, M, Maluquer, C, Pedrazzoli, P, Biello, F, Sinclair, A, Bawany, S, Khalique, S, Rossi, S, Rogers, L, Murphy, C, Belessiotis, K, Carmona-Garcia, MC, Sharkey, R, Garcia-Illescas, D, Rizzo, G, Perachino, M, Saoudi-Gonzalez, N, Doonga, K, Fox, L, Roldan, E, Gaidano, G, Ruiz-Camps, I, Bruna, R, Patriarca, A, Martinez-Vila, C, Cantini, L, Zambelli, A, Giusti, R, Mazzoni, F, Caliman, E, Santoro, A, Grosso, F, Parisi, A, Queirolo, P, Aujayeb, A, Rimassa, L, Prat, A, Tucci, M, Libertini, M, Grisanti, S, Mukherjee, U, Diamantis, N, Fusco, V, Generali, D, Provenzano, S, Gennari, A, Tabernero, J, and Cortellini, A

Abstract

Background The omicron (B.1.1.529) variant of SARS-CoV-2 is highly transmissible and escapes vaccine-induced immunity. We aimed to describe outcomes due to COVID-19 during the omicron outbreak compared with the prevaccination period and alpha (B.1.1.7) and delta (B.1.617.2) waves in patients with cancer in Europe. Methods In this retrospective analysis of the multicentre OnCovid Registry study, we recruited patients aged 18 years or older with laboratory-confirmed diagnosis of SARS-CoV-2, who had a history of solid or haematological malignancy that was either active or in remission. Patient were recruited from 37 oncology centres from UK, Italy, Spain, France, Belgium, and Germany. Participants were followed up from COVID-19 diagnosis until death or loss to follow-up, while being treated as per standard of care. For this analysis, we excluded data from centres that did not actively enter new data after March 1, 2021 (in France, Germany, and Belgium). We compared measures of COVID-19 morbidity, which were complications from COVID-19, hospitalisation due to COVID-19, and requirement of supplemental oxygen and COVID-19-specific therapies, and COVID-19 mortality across three time periods designated as the prevaccination (Feb 27 to Nov 30, 2020), alpha-delta (Dec 1, 2020, to Dec 14, 2021), and omicron (Dec 15, 2021, to Jan 31, 2022) phases. We assessed all-cause case-fatality rates at 14 days and 28 days after diagnosis of COVID-19 overall and in unvaccinated and fully vaccinated patients and in those who received a booster dose, after adjusting for country of origin, sex, age, comorbidities, tumour type, stage, and status, and receipt of systemic anti-cancer therapy. This study is registered with ClinicalTrials.gov, NCT04393974, and is ongoing. Findings As of Feb 4, 2022 (database lock), the registry included 3820 patients who had been diagnosed with COVID-19 between Feb 27, 2020, and Jan 31, 2022. 3473 patients were eligible for inclusion (1640 [47.4%] were women and 1822 [52.6%] were men, with a median age of 68 years [IQR 57-77]). 2033 (58.5%) of 3473 were diagnosed during the prevaccination phase, 1075 (31.0%) during the alpha-delta phase, and 365 (10.5%) during the omicron phase. Among patients diagnosed during the omicron phase, 113 (33.3%) of 339 were fully vaccinated and 165 (48.7%) were boosted, whereas among those diagnosed during the alpha-delta phase, 152 (16.6%) of 915 were fully vaccinated and 21 (2.3%) were boosted. Compared with patients diagnosed during the prevaccination period, those who were diagnosed during the omicron phase had lower case-fatality rates at 14 days (adjusted odds ratio [OR] 0.32 [95% CI 0.19-0.61) and 28 days (0.34 [0.16-0.79]), complications due to COVID-19 (0.26 [0.17-0.46]), and hospitalisation due to COVID-19 (0.17 [0.09-0.32]), and had less requirements for COVID-19-specific therapy (0.22 [0.15-0.34]) and oxygen therapy (0.24 [0.14-0.43]) than did those diagnosed during the alpha-delta phase. Unvaccinated patients diagnosed during the omicron phase had similar crude case-fatality rates at 14 days (ten [25%] of 40 patients vs 114 [17%] of 656) and at 28 days (11 [27%] of 40 vs 184 [28%] of 656) and similar rates of hospitalisation due to COVID-19 (18 [43%] of 42 vs 266 [41%] of 652) and complications from COVID-19 (13 [31%] of 42 vs 237 [36%] of 659) as those diagnosed during the alpha-delta phase. Interpretation Despite time-dependent improvements in outcomes reported in the omicron phase compared with the earlier phases of the pandemic, patients with cancer remain highly susceptible to SARS-CoV-2 if they are not vaccinated against SARS-CoV-2. Our findings support universal vaccination of patients with cancer as a protective measure against morbidity and mortality from COVID-19. Copyright (C) 2022. Published by Elsevier Ltd. All rights reserved.

Published
2022

36. Mode of action of trabectedin in myxoid liposarcomas

Author

Di Giandomenico, S, Frapolli, R, Bello, E, Uboldi, S, Licandro, S A, Marchini, S, Beltrame, L, Brich, S, Mauro, V, Tamborini, E, Pilotti, S, Casali, P G, Grosso, F, Sanfilippo, R, Gronchi, A, Mantovani, R, Gatta, R, Galmarini, C M, Sousa-Faro, J M F, and D'Incalci, M

Published
2014
Full Text
View/download PDF

40. Communication strategies: Explaining the Antimicrobial Resistance to High School Students in a 'One Health' Perspective

Author

Antunes, Patrícia, Silva, A.C., Pereira, B., Areias, C., Gonçalves, C., Ribeiro, M., Barroso, M.T., Leites, S., Rodrigues, L., Novais, Carla, Novais, A., Grosso, F., Ribeiro, T., Mourão, J., Perovic, S., Rebelo, A., Ksiezarek, M., Freitas, A.R., Luisa Peixe, Faculdade de Farmácia, and Faculdade de Ciências da Nutrição e Alimentação

Subjects
Health sciences, Medical and Health sciences, Ciências médicas e da saúde, Medical and Health sciences, Ciências da Saúde, Ciências médicas e da saúde
Published
2021

41. Valutazione e promozione dell’occupabilità sostenibile in Italia

Author

Brondino, M, Pasini, M, Tommasi, F, Picco, E, Grosso, F, Badellino, E, Pistagni, R, Colagiacomo, C, Calicchia, S, Papaleo, B, Signorini, S, Miglioretti, M, Picco Eleonora, Grosso Francesca, Badellino Elisabetta, Pistagni Roberta, Colagiacomo Chiara, Calicchia Sara, Papaleo Bruno, Signorini Stefano, Miglioretti Massimo, Brondino, M, Pasini, M, Tommasi, F, Picco, E, Grosso, F, Badellino, E, Pistagni, R, Colagiacomo, C, Calicchia, S, Papaleo, B, Signorini, S, Miglioretti, M, Picco Eleonora, Grosso Francesca, Badellino Elisabetta, Pistagni Roberta, Colagiacomo Chiara, Calicchia Sara, Papaleo Bruno, Signorini Stefano, and Miglioretti Massimo

Published
2021

42. Valutazione e sviluppo dell’occupabilità sostenibile in Italia

Author

Picco, E, Grosso, F, Badellino, E, Pistagni, R, Colagiacomo, C, Calicchia, S, Papaleo, B, Signorini, S, Miglioretti, M, Eleonora Picco, Francesca Grosso, Elisabetta Badellino, Roberta Pistagni, Chiara Colagiacomo, Sara Calicchia, Bruno Papaleo, Stefano Signorini, Massimo Miglioretti, Picco, E, Grosso, F, Badellino, E, Pistagni, R, Colagiacomo, C, Calicchia, S, Papaleo, B, Signorini, S, Miglioretti, M, Eleonora Picco, Francesca Grosso, Elisabetta Badellino, Roberta Pistagni, Chiara Colagiacomo, Sara Calicchia, Bruno Papaleo, Stefano Signorini, and Massimo Miglioretti

Abstract

Premesse: In una società che invecchia è sempre più importante per aziende, parti sociali e governi promuovere l’occupabilità sostenibile di tutti i lavoratori. Nella letteratura internazionale, la prima definizione di occupabilità sostenibile è stata proposta da Van der Klink et al.: “Per occupabilità sostenibile si intende quanto i lavoratori, durante tutta la loro vita lavorativa, possano raggiungere condizioni di opportunità reali in termini di ampliamento delle proprie capacità, beneficiandone personalmente e restituendo prestazioni di qualità alle realtà aziendali, ora e nel futuro, salvaguardando nel contempo il proprio benessere e la propria salute” (2015). Hazelzet et al., in un lavoro di revisione della letteratura e riprendendo la definizione di van der Klink et al., hanno individuato quattro componenti chiave o aspetti che rendono un lavoratore occupato in modo sostenibile: la salute (benessere, stile di vita, vitalità), la produttività (engagement, work ability), il lavoro di valore (motivazione, competenze, conoscenze) e la prospettiva di lungo periodo (2019). In Italia, tale costrutto è ancora poco conosciuto, così come agli albori sono gli studi che si propongono di sviluppare strumenti specifici con la finalità di monitorare l’occupabilità sostenibile dei lavoratori (uno di questi strumenti è il Il MAastricht Instrument for Sustainable Employability, MAISE-NL Houkes et al. 2020, MAISE-IT Picco et al. submitted). Obiettivi: Lo studio, in collaborazione tra il Dipartimento di Psicologia dell’Università di Milano-Bicocca e INAIL, si propone di identificare, sviluppare, sperimentare e valutare un modello di occupabilità sostenibile presso un campione di imprese e definire orientamenti per l’implementazione dell’occupabilità sostenibile presso le organizzazioni. In particolare, si svilupperà uno studio quali-quantitativo finalizzato a identificare e analizzare i fattori che determinano l’occupabilità sostenibile, sviluppare un ques

Published
2021

47. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Author

De Placido, S, Gallo, C, De Laurentiis, M, Bisagni, G, Arpino, G, Sarobba, M, Riccardi, F, Russo, A, Del Mastro, L, Cogoni, A, Cognetti, F, Gori, S, Foglietta, J, Frassoldati, A, Amoroso, D, Laudadio, L, Moscetti, L, Montemurro, F, Verusio, C, Bernardo, A, Lorusso, V, Gravina, A, Moretti, G, Lauria, R, Lai, A, Mocerino, C, Rizzo, S, Nuzzo, F, Carlini, P, Perrone, F, Accurso, A, Agostara, B, Aieta, M, Alabiso, O, Alicicco, M, Amadori, D, Amaducci, L, Amiconi, G, Antuzzi, G, Ardine, M, Ardizzoia, A, Aversa, C, Badalamenti, G, Barni, S, Basurto, C, Berardi, R, Bergamasco, C, Bidoli, P, Bighin, C, Biondi, E, Boni, C, Borgonovo, K, Botta, M, Bravi, S, Bruzzi, P, Buono, G, Butera, A, Caldara, A, Candeloro, G, Cappelletti, C, Cardalesi, C, Carfora, E, Cariello, A, Carrozza, F, Carteni, G, Caruso, M, Casadei, V, Casanova, C, Castori, L, Cavanna, L, Cavazzini, G, Cazzaniga, M, Chilelli, M, Chiodini, P, Chiorrini, S, Ciardiello, F, Ciccarese, M, Cinieri, S, Clerico, M, Coccaro, M, Comande, M, Corbo, C, Cortino, G, Cusenza, S, Daniele, G, D'Arco, A, D'Auria, G, Dazzi, C, De Angelis, C, de Braud, F, De Feo, G, De Matteis, A, De Tursi, M, Di Blasio, A, di Lucca, G, Di Lullo, L, Di Rella, F, Di Renzo, G, Di Stefano, P, Di Stefano, A, Diana, A, Donati, S, Fabbri, A, Fabi, A, Faedi, M, Farina, G, Farris, A, Febbraro, A, Fedele, P, Federico, P, Ferrau, F, Ferretti, G, Ferro, A, Floriani, I, Forcignano, R, Forciniti, S, Forestieri, V, Fornari, G, Frisinghelli, M, Fusco, V, Gallizzi, G, Galvano, A, Gambardella, A, Gambi, A, Gebbia, V, Gervasi, E, Ghilardi, M, Giacobino, A, Giardina, G, Giotta, F, Giraudi, S, Giuliano, M, Grassadonia, A, Grasso, D, Grosso, F, Guizzaro, L, Incoronato, P, Incorvaia, L, Iodice, G, La Verde, N, Labonia, V, Landi, G, Latorre, A, Leonardi, V, Levaggi, A, Limite, G, Lina Bascialla, L, Livi, L, Maiello, E, Mandelli, D, Marcon, I, Menon, D, Montedoro, M, Moraca, L, Moretti, A, Morritti, M, Morselli, P, Mura, A, Mura, S, Musacchio, M, Muzio, A, Natale, D, Natoli, C, Nigro, C, Nistico, C, Nuzzo, A, Orditura, M, Orlando, L, Pacilio, C, Palumbo, G, Palumbo, R, Pasini, F, Paterno, E, Pazzola, A, Pelliccioni, S, Pensabene, M, Perroni, D, Pesenti Gritti, A, Petrelli, F, Piccirillo, M, Pinotti, G, Pogliani, C, Poli, D, Prader, S, Recchia, F, Rizzi, D, Romano, C, Rossello, R, Rossini, C, Salvucci, G, Sanna, V, Santini, A, Saracchini, S, Savastano, C, Scambia, G, Schettini, F, Schiavone, P, Schirone, A, Seles, E, Signoriello, S, Signoriello, G, Silva, R, Silvestri, A, Simeon, V, Spagnoletti, I, Tamberi, S, Teragni, C, Thalmann, V, Thomas, R, Thomas, G, Tienghi, A, Tinari, N, Tinessa, V, Tomei, F, Tonini, G, Torri, V, Traficante, D, Tudini, M, Turazza, M, Vignoli, R, Vitale, M, Zacchia, A, Zagarese, P, Zanni, A, Zavallone, L, Zavettieri, M, Zoboli, A, De Placido S., Gallo C., De Laurentiis M., Bisagni G., Arpino G., Sarobba M. G., Riccardi F., Russo A., Del Mastro L., Cogoni A. A., Cognetti F., Gori S., Foglietta J., Frassoldati A., Amoroso D., Laudadio L., Moscetti L., Montemurro F., Verusio C., Bernardo A., Lorusso V., Gravina A., Moretti G., Lauria R., Lai A., Mocerino C., Rizzo S., Nuzzo F., Carlini P., Perrone F., Accurso A., Agostara B., Aieta M., Alabiso O., Alicicco M. G., Amadori D., Amaducci L., Amiconi G., Antuzzi G., Ardine M., Ardizzoia A., Aversa C., Badalamenti G., Barni S., Basurto C., Berardi R., Bergamasco C., Bidoli P., Bighin C., Biondi E., Boni C., Borgonovo K., Botta M., Bravi S., Bruzzi P., Buono G., Butera A., Caldara A., Candeloro G., Cappelletti C., Cardalesi C., Carfora E., Cariello A., Carrozza F., Carteni G., Caruso M., Casadei V., Casanova C., Castori L., Cavanna L., Cavazzini G., Cazzaniga M., Chilelli M., Chiodini P., Chiorrini S., Ciardiello F., Ciccarese M., Cinieri S., Clerico M., Coccaro M., Comande M., Corbo C., Cortino G., Cusenza S., Daniele G., D'arco A. M., D'auria G., Dazzi C., De Angelis C., de Braud F., De Feo G., De Matteis A., De Tursi M., Di Blasio A., di Lucca G., Di Lullo L., Di Rella F., Di Renzo G., Di Stefano P., Di Stefano A., Diana A., Donati S., Fabbri A., Fabi A., Faedi M., Farina G., Farris A., Febbraro A., Fedele P., Federico P., Ferrau F., Ferretti G., Ferro A., Floriani I., Forcignano R., Forciniti S., Forestieri V., Fornari G., Frisinghelli M., Fusco V., Gallizzi G., Galvano A., Gambardella A., Gambi A., Gebbia V., Gervasi E., Ghilardi M., Giacobino A., Giardina G., Giotta F., Giraudi S., Giuliano M., Grassadonia A., Grasso D., Grosso F., Guizzaro L., Incoronato P., Incorvaia L., Iodice G., La Verde N., Labonia V., Landi G., Latorre A., Leonardi V., Levaggi A., Limite G., Lina Bascialla L., Livi L., Maiello E., Mandelli D., Marcon I., Menon D., Montedoro M., Moraca L., Moretti A., Morritti M. G., Morselli P., Mura A., Mura S., Musacchio M., Muzio A., Natale D., Natoli C., Nigro C., Nistico C., Nuzzo A., Orditura M., Orlando L., Pacilio C., Palumbo G., Palumbo R., Pasini F., Paterno E., Pazzola A., Pelliccioni S., Pensabene M., Perroni D., Pesenti Gritti A., Petrelli F., Piccirillo M. C., Pinotti G., Pogliani C., Poli D., Prader S., Recchia F., Rizzi D., Romano C., Rossello R., Rossini C., Salvucci G., Sanna V., Santini A., Saracchini S., Savastano C., Scambia G., Schettini F., Schiavone P., Schirone A., Seles E., Signoriello S., Signoriello G., Silva R. R., Silvestri A., Simeon V., Spagnoletti I., Tamberi S., Teragni C., Thalmann V., Thomas R., Thomas G., Tienghi A., Tinari N., Tinessa V., Tomei F., Tonini G., Torri V., Traficante D., Tudini M., Turazza M., Vignoli R., Vitale M. G., Zacchia A., Zagarese P., Zanni A., Zavallone L., Zavettieri M., Zoboli A., De Placido, S, Gallo, C, De Laurentiis, M, Bisagni, G, Arpino, G, Sarobba, M, Riccardi, F, Russo, A, Del Mastro, L, Cogoni, A, Cognetti, F, Gori, S, Foglietta, J, Frassoldati, A, Amoroso, D, Laudadio, L, Moscetti, L, Montemurro, F, Verusio, C, Bernardo, A, Lorusso, V, Gravina, A, Moretti, G, Lauria, R, Lai, A, Mocerino, C, Rizzo, S, Nuzzo, F, Carlini, P, Perrone, F, Accurso, A, Agostara, B, Aieta, M, Alabiso, O, Alicicco, M, Amadori, D, Amaducci, L, Amiconi, G, Antuzzi, G, Ardine, M, Ardizzoia, A, Aversa, C, Badalamenti, G, Barni, S, Basurto, C, Berardi, R, Bergamasco, C, Bidoli, P, Bighin, C, Biondi, E, Boni, C, Borgonovo, K, Botta, M, Bravi, S, Bruzzi, P, Buono, G, Butera, A, Caldara, A, Candeloro, G, Cappelletti, C, Cardalesi, C, Carfora, E, Cariello, A, Carrozza, F, Carteni, G, Caruso, M, Casadei, V, Casanova, C, Castori, L, Cavanna, L, Cavazzini, G, Cazzaniga, M, Chilelli, M, Chiodini, P, Chiorrini, S, Ciardiello, F, Ciccarese, M, Cinieri, S, Clerico, M, Coccaro, M, Comande, M, Corbo, C, Cortino, G, Cusenza, S, Daniele, G, D'Arco, A, D'Auria, G, Dazzi, C, De Angelis, C, de Braud, F, De Feo, G, De Matteis, A, De Tursi, M, Di Blasio, A, di Lucca, G, Di Lullo, L, Di Rella, F, Di Renzo, G, Di Stefano, P, Di Stefano, A, Diana, A, Donati, S, Fabbri, A, Fabi, A, Faedi, M, Farina, G, Farris, A, Febbraro, A, Fedele, P, Federico, P, Ferrau, F, Ferretti, G, Ferro, A, Floriani, I, Forcignano, R, Forciniti, S, Forestieri, V, Fornari, G, Frisinghelli, M, Fusco, V, Gallizzi, G, Galvano, A, Gambardella, A, Gambi, A, Gebbia, V, Gervasi, E, Ghilardi, M, Giacobino, A, Giardina, G, Giotta, F, Giraudi, S, Giuliano, M, Grassadonia, A, Grasso, D, Grosso, F, Guizzaro, L, Incoronato, P, Incorvaia, L, Iodice, G, La Verde, N, Labonia, V, Landi, G, Latorre, A, Leonardi, V, Levaggi, A, Limite, G, Lina Bascialla, L, Livi, L, Maiello, E, Mandelli, D, Marcon, I, Menon, D, Montedoro, M, Moraca, L, Moretti, A, Morritti, M, Morselli, P, Mura, A, Mura, S, Musacchio, M, Muzio, A, Natale, D, Natoli, C, Nigro, C, Nistico, C, Nuzzo, A, Orditura, M, Orlando, L, Pacilio, C, Palumbo, G, Palumbo, R, Pasini, F, Paterno, E, Pazzola, A, Pelliccioni, S, Pensabene, M, Perroni, D, Pesenti Gritti, A, Petrelli, F, Piccirillo, M, Pinotti, G, Pogliani, C, Poli, D, Prader, S, Recchia, F, Rizzi, D, Romano, C, Rossello, R, Rossini, C, Salvucci, G, Sanna, V, Santini, A, Saracchini, S, Savastano, C, Scambia, G, Schettini, F, Schiavone, P, Schirone, A, Seles, E, Signoriello, S, Signoriello, G, Silva, R, Silvestri, A, Simeon, V, Spagnoletti, I, Tamberi, S, Teragni, C, Thalmann, V, Thomas, R, Thomas, G, Tienghi, A, Tinari, N, Tinessa, V, Tomei, F, Tonini, G, Torri, V, Traficante, D, Tudini, M, Turazza, M, Vignoli, R, Vitale, M, Zacchia, A, Zagarese, P, Zanni, A, Zavallone, L, Zavettieri, M, Zoboli, A, De Placido S., Gallo C., De Laurentiis M., Bisagni G., Arpino G., Sarobba M. G., Riccardi F., Russo A., Del Mastro L., Cogoni A. A., Cognetti F., Gori S., Foglietta J., Frassoldati A., Amoroso D., Laudadio L., Moscetti L., Montemurro F., Verusio C., Bernardo A., Lorusso V., Gravina A., Moretti G., Lauria R., Lai A., Mocerino C., Rizzo S., Nuzzo F., Carlini P., Perrone F., Accurso A., Agostara B., Aieta M., Alabiso O., Alicicco M. G., Amadori D., Amaducci L., Amiconi G., Antuzzi G., Ardine M., Ardizzoia A., Aversa C., Badalamenti G., Barni S., Basurto C., Berardi R., Bergamasco C., Bidoli P., Bighin C., Biondi E., Boni C., Borgonovo K., Botta M., Bravi S., Bruzzi P., Buono G., Butera A., Caldara A., Candeloro G., Cappelletti C., Cardalesi C., Carfora E., Cariello A., Carrozza F., Carteni G., Caruso M., Casadei V., Casanova C., Castori L., Cavanna L., Cavazzini G., Cazzaniga M., Chilelli M., Chiodini P., Chiorrini S., Ciardiello F., Ciccarese M., Cinieri S., Clerico M., Coccaro M., Comande M., Corbo C., Cortino G., Cusenza S., Daniele G., D'arco A. M., D'auria G., Dazzi C., De Angelis C., de Braud F., De Feo G., De Matteis A., De Tursi M., Di Blasio A., di Lucca G., Di Lullo L., Di Rella F., Di Renzo G., Di Stefano P., Di Stefano A., Diana A., Donati S., Fabbri A., Fabi A., Faedi M., Farina G., Farris A., Febbraro A., Fedele P., Federico P., Ferrau F., Ferretti G., Ferro A., Floriani I., Forcignano R., Forciniti S., Forestieri V., Fornari G., Frisinghelli M., Fusco V., Gallizzi G., Galvano A., Gambardella A., Gambi A., Gebbia V., Gervasi E., Ghilardi M., Giacobino A., Giardina G., Giotta F., Giraudi S., Giuliano M., Grassadonia A., Grasso D., Grosso F., Guizzaro L., Incoronato P., Incorvaia L., Iodice G., La Verde N., Labonia V., Landi G., Latorre A., Leonardi V., Levaggi A., Limite G., Lina Bascialla L., Livi L., Maiello E., Mandelli D., Marcon I., Menon D., Montedoro M., Moraca L., Moretti A., Morritti M. G., Morselli P., Mura A., Mura S., Musacchio M., Muzio A., Natale D., Natoli C., Nigro C., Nistico C., Nuzzo A., Orditura M., Orlando L., Pacilio C., Palumbo G., Palumbo R., Pasini F., Paterno E., Pazzola A., Pelliccioni S., Pensabene M., Perroni D., Pesenti Gritti A., Petrelli F., Piccirillo M. C., Pinotti G., Pogliani C., Poli D., Prader S., Recchia F., Rizzi D., Romano C., Rossello R., Rossini C., Salvucci G., Sanna V., Santini A., Saracchini S., Savastano C., Scambia G., Schettini F., Schiavone P., Schirone A., Seles E., Signoriello S., Signoriello G., Silva R. R., Silvestri A., Simeon V., Spagnoletti I., Tamberi S., Teragni C., Thalmann V., Thomas R., Thomas G., Tienghi A., Tinari N., Tinessa V., Tomei F., Tonini G., Torri V., Traficante D., Tudini M., Turazza M., Vignoli R., Vitale M. G., Zacchia A., Zagarese P., Zanni A., Zavallone L., Zavettieri M., and Zoboli A.

Abstract

Background: Uncertainty exists about the optimal schedule of adjuvant treatment of breast cancer with aromatase inhibitors and, to our knowledge, no trial has directly compared the three aromatase inhibitors anastrozole, exemestane, and letrozole. We investigated the schedule and type of aromatase inhibitors to be used as adjuvant treatment for hormone receptor-positive early breast cancer. Methods: FATA-GIM3 is a multicentre, open-label, randomised, phase 3 trial of six different treatments in postmenopausal women with hormone receptor-positive early breast cancer. Eligible patients had histologically confirmed invasive hormone receptor-positive breast cancer that had been completely removed by surgery, any pathological tumour size, and axillary nodal status. Key exclusion criteria were hormone replacement therapy, recurrent or metastatic disease, previous treatment with tamoxifen, and another malignancy in the previous 10 years. Patients were randomly assigned in an equal ratio to one of six treatment groups: oral anastrozole (1 mg per day), exemestane (25 mg per day), or letrozole (2·5 mg per day) tablets upfront for 5 years (upfront strategy) or oral tamoxifen (20 mg per day) for 2 years followed by oral administration of one of the three aromatase inhibitors for 3 years (switch strategy). Randomisation was done by a computerised minimisation procedure stratified for oestrogen receptor, progesterone receptor, and HER2 status; previous chemotherapy; and pathological nodal status. Neither the patients nor the physicians were masked to treatment allocation. The primary endpoint was disease-free survival. The minimum cutoff to declare superiority of the upfront strategy over the switch strategy was assumed to be a 2% difference in disease-free survival at 5 years. Primary efficacy analyses were done by intention to treat; safety analyses included all patients for whom at least one safety case report form had been completed. Follow-up is ongoing. This trial is regist

Published
2018

48. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial

Author

Cardinale, D, Ciceri, F, Latini, R, Franzosi, M, Sandri, M, Civelli, M, Cucchi, G, Menatti, E, Mangiavacchi, M, Cavina, R, Barbieri, E, Gori, S, Colombo, A, Curigliano, G, Salvatici, M, Rizzo, A, Ghisoni, F, Bianchi, A, Falci, C, Aquilina, M, Rocca, A, Monopoli, A, Milandri, C, Rossetti, G, Bregni, M, Malossi, A, Nassiacos, D, Verusio, C, Giordano, M, Staszewsky, L, Barlera, S, Nicolis, E, Magnoli, M, Masson, S, Cipolla, C, Curigliano, Sicuro, M, Rossetti, Maggioni, A, Labianca, R, Tettamanti, M, Senni, M, Finzi, A, Grosso, F, Vago, T, Gramenzi, S, Balconi, G, Bernasconi, R, Buratti, M, Ojeda-Fernandez, M, Vasami, A, Thiebat, B, Bare, C, Corzani, A, Coccolo, F, Colecchia, S, Pellegrini, C, Appio, L, Caico, I, Mesenzani, O, Campana, C, Gilardoni, M, Scognamiglio, G, Corrado, G, Battagin, D, De Rosa, F, Carpino, C, Palazzo, S, Giannessi, P, Zipoli, G, Pastori, P, Callegari, S, Sesenna, C, Fodor, C, Guiducci, D, Mazza, R, Turazza, F, Vallerio, P, Marbello, L, Sala, E, Fragasso, G, Trinca, S, Farolfi, A, Andreis, D, Lanzoni, L, Marchetti, F, Mioranza, E, Banzato, A, Re, F, Gaibazzi, N, Gullo, M, Turina, M, Gervasi, E, Giaroli, F, Barco, B, Bertolini, A, Sinagra, G, Aleksova, A, Guglielmi, A, Pinotti, G, Gueli, R, Mongiardi, C, Vallini, I, Cardinale D., Ciceri F., Latini R., Franzosi M. G., Sandri M. T., Civelli M., Cucchi G., Menatti E., Mangiavacchi M., Cavina R., Barbieri E., Gori S., Colombo A., Curigliano G., Salvatici M., Rizzo A., Ghisoni F., Bianchi A., Falci C., Aquilina M., Rocca A., Monopoli A., Milandri C., Rossetti G., Bregni M., Malossi A., Nassiacos D., Verusio C., Giordano M., Staszewsky L., Barlera S., Nicolis E. B., Magnoli M., Masson S., Cipolla C. M., Sicuro M., Maggioni A. P., Labianca R., Tettamanti M., Senni M., Finzi A., Grosso F., Vago T., Gramenzi S., Balconi G., Bernasconi R., Nicolis E., Buratti M. G., Ojeda-Fernandez M. L., Vasami A., Thiebat B., Bare C., Corzani A., Coccolo F., Colecchia S., Pellegrini C., Appio L., Caico I., Mesenzani O., Campana C., Gilardoni M., Scognamiglio G., Corrado G., Battagin D., De Rosa F., Carpino C., Palazzo S., Giannessi P. G., Zipoli G., Pastori P., Callegari S., Sesenna C., Fodor C., Guiducci D., Mazza R., Turazza F. M., Vallerio P., Marbello L., Sala E., Fragasso G., Trinca S., Farolfi A., Andreis D., Lanzoni L., Marchetti F., Mioranza E., Banzato A., Re F., Gaibazzi N., Gullo M., Turina M. C., Gervasi E., Giaroli F., Barco B., Bertolini A., Sinagra G., Aleksova A., Guglielmi A., Pinotti G., Gueli R., Mongiardi C., Vallini I., Cardinale, D, Ciceri, F, Latini, R, Franzosi, M, Sandri, M, Civelli, M, Cucchi, G, Menatti, E, Mangiavacchi, M, Cavina, R, Barbieri, E, Gori, S, Colombo, A, Curigliano, G, Salvatici, M, Rizzo, A, Ghisoni, F, Bianchi, A, Falci, C, Aquilina, M, Rocca, A, Monopoli, A, Milandri, C, Rossetti, G, Bregni, M, Malossi, A, Nassiacos, D, Verusio, C, Giordano, M, Staszewsky, L, Barlera, S, Nicolis, E, Magnoli, M, Masson, S, Cipolla, C, Curigliano, Sicuro, M, Rossetti, Maggioni, A, Labianca, R, Tettamanti, M, Senni, M, Finzi, A, Grosso, F, Vago, T, Gramenzi, S, Balconi, G, Bernasconi, R, Buratti, M, Ojeda-Fernandez, M, Vasami, A, Thiebat, B, Bare, C, Corzani, A, Coccolo, F, Colecchia, S, Pellegrini, C, Appio, L, Caico, I, Mesenzani, O, Campana, C, Gilardoni, M, Scognamiglio, G, Corrado, G, Battagin, D, De Rosa, F, Carpino, C, Palazzo, S, Giannessi, P, Zipoli, G, Pastori, P, Callegari, S, Sesenna, C, Fodor, C, Guiducci, D, Mazza, R, Turazza, F, Vallerio, P, Marbello, L, Sala, E, Fragasso, G, Trinca, S, Farolfi, A, Andreis, D, Lanzoni, L, Marchetti, F, Mioranza, E, Banzato, A, Re, F, Gaibazzi, N, Gullo, M, Turina, M, Gervasi, E, Giaroli, F, Barco, B, Bertolini, A, Sinagra, G, Aleksova, A, Guglielmi, A, Pinotti, G, Gueli, R, Mongiardi, C, Vallini, I, Cardinale D., Ciceri F., Latini R., Franzosi M. G., Sandri M. T., Civelli M., Cucchi G., Menatti E., Mangiavacchi M., Cavina R., Barbieri E., Gori S., Colombo A., Curigliano G., Salvatici M., Rizzo A., Ghisoni F., Bianchi A., Falci C., Aquilina M., Rocca A., Monopoli A., Milandri C., Rossetti G., Bregni M., Malossi A., Nassiacos D., Verusio C., Giordano M., Staszewsky L., Barlera S., Nicolis E. B., Magnoli M., Masson S., Cipolla C. M., Sicuro M., Maggioni A. P., Labianca R., Tettamanti M., Senni M., Finzi A., Grosso F., Vago T., Gramenzi S., Balconi G., Bernasconi R., Nicolis E., Buratti M. G., Ojeda-Fernandez M. L., Vasami A., Thiebat B., Bare C., Corzani A., Coccolo F., Colecchia S., Pellegrini C., Appio L., Caico I., Mesenzani O., Campana C., Gilardoni M., Scognamiglio G., Corrado G., Battagin D., De Rosa F., Carpino C., Palazzo S., Giannessi P. G., Zipoli G., Pastori P., Callegari S., Sesenna C., Fodor C., Guiducci D., Mazza R., Turazza F. M., Vallerio P., Marbello L., Sala E., Fragasso G., Trinca S., Farolfi A., Andreis D., Lanzoni L., Marchetti F., Mioranza E., Banzato A., Re F., Gaibazzi N., Gullo M., Turina M. C., Gervasi E., Giaroli F., Barco B., Bertolini A., Sinagra G., Aleksova A., Guglielmi A., Pinotti G., Gueli R., Mongiardi C., and Vallini I.

Abstract

Background: Troponin changes over time have been suggested to allow for an early diagnosis of cardiac injury ensuing cancer chemotherapy; cancer patients with troponin elevation may benefit of therapy with enalapril. It is unknown whether a preventive treatment with enalapril may further increase the benefit. Methods: The International CardioOncology Society-one trial (ICOS-ONE) was a controlled, open-label trial conducted in 21 Italian hospitals. Patients were randomly assigned to two strategies: enalapril in all patients started before chemotherapy (CT; ‘prevention’ arm), and enalapril started only in patients with an increase in troponin during or after CT (‘troponin-triggered’ arm). Troponin was assayed locally in 2596 blood samples, before and after each anthracycline-containing CT cycle and at each study visit; electrocardiogram and echocardiogram were done at baseline, and at 1, 3, 6 and 12-month follow-up. Primary outcome was the incidence of troponin elevation above the threshold. Findings: Of the 273 patients, 88% were women, mean age 51 ± 12 years. The majority (76%) had breast cancer, 3% had a history of hypertension and 4% were diabetic. Epirubicin and doxorubicin were most commonly prescribed, with median cumulative doses of 360 [270–360] and 240 [240–240] mg/m2, respectively. The incidence of troponin elevation was 23% in the prevention and 26% in the troponin-triggered group (p = 0.50). Three patients (1.1%) -two in the prevention, one in the troponin-triggered group-developed cardiotoxicity, defined as 10% point reduction of LV ejection fraction, with values lower than 50%. Interpretation: Low cumulative doses of anthracyclines in adult patients with low cardiovascular risk can raise troponins, without differences between the two strategies of giving enalapril. Considering a benefit of enalapril in the prevention of LV dysfunction, a troponin-triggered strategy may be more convenient.

Published
2018

49. Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents

Author

Uboldi, S., Bernasconi, S., Romano, M., Marchini, S., Nerini, I. Fuso, Damia, G., Ganzinelli, M., Marangon, E., Sala, F., Clivio, L., Chiorino, G., Giandomenico, Di S., Rocchi, M., Capozzi, O., Margison, G. P., Watson, A. J., Caccuri, A. M., Pastore, A., Fossati, A., Mantovani, R., Grosso, F., Tercero, J. C., Erba, E., and DʼIncalci, M.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results